OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Potential serotonergic agents for the treatment of schizophrenia
Ricardo P. Garay, Michel Bourin, Evelyne de Paillette, et al.
Expert Opinion on Investigational Drugs (2015) Vol. 25, Iss. 2, pp. 159-170
Closed Access | Times Cited: 39
Ricardo P. Garay, Michel Bourin, Evelyne de Paillette, et al.
Expert Opinion on Investigational Drugs (2015) Vol. 25, Iss. 2, pp. 159-170
Closed Access | Times Cited: 39
Showing 1-25 of 39 citing articles:
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Albert C. Yang, Shih‐Jen Tsai
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 8, pp. 1689-1689
Open Access | Times Cited: 248
Albert C. Yang, Shih‐Jen Tsai
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 8, pp. 1689-1689
Open Access | Times Cited: 248
Pivotal mental states
Ari Brouwer, Robin Carhart‐Harris
Journal of Psychopharmacology (2020) Vol. 35, Iss. 4, pp. 319-352
Open Access | Times Cited: 113
Ari Brouwer, Robin Carhart‐Harris
Journal of Psychopharmacology (2020) Vol. 35, Iss. 4, pp. 319-352
Open Access | Times Cited: 113
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Rita Kočárová, Jiřı́ Horáček, Robin Carhart‐Harris
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 68
Rita Kočárová, Jiřı́ Horáček, Robin Carhart‐Harris
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 68
Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases
David Vanda, Paweł Zajdel, Miroslav Soural
European Journal of Medicinal Chemistry (2019) Vol. 181, pp. 111569-111569
Closed Access | Times Cited: 75
David Vanda, Paweł Zajdel, Miroslav Soural
European Journal of Medicinal Chemistry (2019) Vol. 181, pp. 111569-111569
Closed Access | Times Cited: 75
Investigational drugs in recent clinical trials for treatment-resistant depression
Ricardo P. Garay, Carlos A. Zarate, Thomas Charpeaud, et al.
Expert Review of Neurotherapeutics (2017) Vol. 17, Iss. 6, pp. 593-609
Open Access | Times Cited: 71
Ricardo P. Garay, Carlos A. Zarate, Thomas Charpeaud, et al.
Expert Review of Neurotherapeutics (2017) Vol. 17, Iss. 6, pp. 593-609
Open Access | Times Cited: 71
Up-to-date expert opinion on the safety of recently developed antipsychotics
Laura Orsolini, Domenico De Berardis, Umberto Volpe
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 8, pp. 981-998
Closed Access | Times Cited: 48
Laura Orsolini, Domenico De Berardis, Umberto Volpe
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 8, pp. 981-998
Closed Access | Times Cited: 48
Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review
Kevin Kyle, Jeff M. Bronstein
Parkinsonism & Related Disorders (2020) Vol. 75, pp. 55-62
Closed Access | Times Cited: 47
Kevin Kyle, Jeff M. Bronstein
Parkinsonism & Related Disorders (2020) Vol. 75, pp. 55-62
Closed Access | Times Cited: 47
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
Joshua T. Kantrowitz
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 947-959
Closed Access | Times Cited: 40
Joshua T. Kantrowitz
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 947-959
Closed Access | Times Cited: 40
The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson’s Disease
Nevena Divac, Radan Stojanović, Katarina Savić Vujović, et al.
Behavioural Neurology (2016) Vol. 2016, pp. 1-6
Open Access | Times Cited: 46
Nevena Divac, Radan Stojanović, Katarina Savić Vujović, et al.
Behavioural Neurology (2016) Vol. 2016, pp. 1-6
Open Access | Times Cited: 46
Are Circadian Disturbances a Core Pathophysiological Component of Schizophrenia?
Tara C. Delorme, Lalit K. Srivastava, Nicolas Cermakian
Journal of Biological Rhythms (2020) Vol. 35, Iss. 4, pp. 325-339
Open Access | Times Cited: 32
Tara C. Delorme, Lalit K. Srivastava, Nicolas Cermakian
Journal of Biological Rhythms (2020) Vol. 35, Iss. 4, pp. 325-339
Open Access | Times Cited: 32
An overview on the synthetic and medicinal perspectives of indenopyrazoles
Irfan Khan, Mohd Adil Shareef, C. Ganesh Kumar
European Journal of Medicinal Chemistry (2019) Vol. 178, pp. 1-12
Closed Access | Times Cited: 26
Irfan Khan, Mohd Adil Shareef, C. Ganesh Kumar
European Journal of Medicinal Chemistry (2019) Vol. 178, pp. 1-12
Closed Access | Times Cited: 26
Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment
Karin Hrovatin, Tanja Kunej, Vita Dolžan
American Journal of Medical Genetics Part B Neuropsychiatric Genetics (2019) Vol. 183, Iss. 2, pp. 113-127
Closed Access | Times Cited: 26
Karin Hrovatin, Tanja Kunej, Vita Dolžan
American Journal of Medical Genetics Part B Neuropsychiatric Genetics (2019) Vol. 183, Iss. 2, pp. 113-127
Closed Access | Times Cited: 26
Endocannabinoid-serotonin systems interaction in health and disease
Roberto Colangeli, G. Campbell Teskey, Giuseppe Di Giovanni
Progress in brain research (2021), pp. 83-134
Closed Access | Times Cited: 23
Roberto Colangeli, G. Campbell Teskey, Giuseppe Di Giovanni
Progress in brain research (2021), pp. 83-134
Closed Access | Times Cited: 23
Genetics of Aggression in Alzheimer’s Disease (AD)
Walter J. Lukiw, Е. И. Рогаев
Frontiers in Aging Neuroscience (2017) Vol. 9
Open Access | Times Cited: 22
Walter J. Lukiw, Е. И. Рогаев
Frontiers in Aging Neuroscience (2017) Vol. 9
Open Access | Times Cited: 22
Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties
Paweł Zajdel, Katarzyna Grychowska, Szczepan Mogilski, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13279-13298
Open Access | Times Cited: 17
Paweł Zajdel, Katarzyna Grychowska, Szczepan Mogilski, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13279-13298
Open Access | Times Cited: 17
Frameworking memory and serotonergic markers
Alfredo Meneses
Reviews in the Neurosciences (2017) Vol. 28, Iss. 5, pp. 455-497
Closed Access | Times Cited: 18
Alfredo Meneses
Reviews in the Neurosciences (2017) Vol. 28, Iss. 5, pp. 455-497
Closed Access | Times Cited: 18
Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics
Xudong Cao, Yin Chen, Yifang Zhang, et al.
European Journal of Medicinal Chemistry (2016) Vol. 124, pp. 713-728
Closed Access | Times Cited: 15
Xudong Cao, Yin Chen, Yifang Zhang, et al.
European Journal of Medicinal Chemistry (2016) Vol. 124, pp. 713-728
Closed Access | Times Cited: 15
Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)
Dominik Strzelecki, Małgorzata Urban‐Kowalczyk, Adam Wysokiński
Psychiatry Research (2018) Vol. 268, pp. 447-453
Closed Access | Times Cited: 15
Dominik Strzelecki, Małgorzata Urban‐Kowalczyk, Adam Wysokiński
Psychiatry Research (2018) Vol. 268, pp. 447-453
Closed Access | Times Cited: 15
Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis
Harini Sarva, Claire Henchcliffe
Therapeutic Advances in Neurological Disorders (2016) Vol. 9, Iss. 6, pp. 462-473
Open Access | Times Cited: 14
Harini Sarva, Claire Henchcliffe
Therapeutic Advances in Neurological Disorders (2016) Vol. 9, Iss. 6, pp. 462-473
Open Access | Times Cited: 14
Chemical puzzles in the search for new, flexible derivatives of lurasidone as antipsychotic drugs
Przemysław Zaręba, Anna K. Drabczyk, Jolanta Jaśkowska, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 28, Iss. 10, pp. 115459-115459
Open Access | Times Cited: 13
Przemysław Zaręba, Anna K. Drabczyk, Jolanta Jaśkowska, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 28, Iss. 10, pp. 115459-115459
Open Access | Times Cited: 13
The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia
Michael Davidson
Dialogues in Clinical Neuroscience (2018) Vol. 20, Iss. 3, pp. 215-221
Open Access | Times Cited: 14
Michael Davidson
Dialogues in Clinical Neuroscience (2018) Vol. 20, Iss. 3, pp. 215-221
Open Access | Times Cited: 14
Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands
Gianfabio Giorgioni, Alessandro Bonifazi, Luca Botticelli, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2640-2706
Closed Access | Times Cited: 1
Gianfabio Giorgioni, Alessandro Bonifazi, Luca Botticelli, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2640-2706
Closed Access | Times Cited: 1
New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease
Raquel N. Taddei, F. Spinnato, Peter Jenner
International review of neurobiology (2017), pp. 407-452
Closed Access | Times Cited: 9
Raquel N. Taddei, F. Spinnato, Peter Jenner
International review of neurobiology (2017), pp. 407-452
Closed Access | Times Cited: 9
Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies
Agnieszka Jankowska, Grzegorz Satała, Anna Partyka, et al.
Current Medicinal Chemistry (2019) Vol. 26, Iss. 25, pp. 4885-4913
Closed Access | Times Cited: 9
Agnieszka Jankowska, Grzegorz Satała, Anna Partyka, et al.
Current Medicinal Chemistry (2019) Vol. 26, Iss. 25, pp. 4885-4913
Closed Access | Times Cited: 9
